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Abstract 
Background: CD24, a mucin-like membrane glycoprotein, plays a critical role in carcinogenesis, but its role in human 
gastric cancer and the underlying mechanism remains undefined.
Methods: The contents of CD24 and epidermal growth factor receptor (EGFR) in gastric cancer cells (SGC-7901 and 
BGC-823) and non-malignant gastric epithelial cells (GES-1) were evaluated by Western blotting assay. Cellular EGFR 
staining was examined by immunofluorescence assay. Cell migration rate was measured by wound healing assay. 
The effects of depletion/overexperssion of CD24 on EGFR expression and activation of EGF/EGFR singaling pathways 
were evaluated by immunofluorescence, qPCR, Western blotting and flow cytometry techniques. RhoA activity was 
assessed by pulldown assay. CD24 and EGFR expression patterns in human gastric tumor samples were also investi-
gated by immunohistochemistry staining.
Results: CD24 was overexpressed in human gastric cancer cells. Ectopic expression of CD24 in gastric epithelial cells 
augmented the expression of EGFR, while knockdown of CD24 in gastric cancer cells decreased the level of EGFR and 
cell migration velocity. To further explore the mechanisms, we investigated the effect of CD24 expression on EGF/
EGFR signaling. We noticed that this effect of CD24 on EGFR expression was dependent on promoting EGFR inter-
nalization and degradation. Lower ERK and Akt phosphorylations in response to EGF stimulation were observed in 
CD24-depleted cells. In addition, we noticed that the effect of CD24 on EGFR stability was mediated by RhoA activity 
in SGC-7901 gastric cancer cells. Analysis of gastric cancer specimens revealed a positive correlation between CD24 
and EGFR levels and an association between CD24 expression and worse prognosis.
Conclusion: Thus, these findings suggest for the first time that CD24 regulates EGFR signaling by inhibiting EGFR 
internalization and degradation in a RhoA-dependent manner in gastric cancer cells.
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Background
Gastric cancer is the second highest cause of cancer-
related mortality worldwide [1]. Although early detection 
was associated with a reduced risk of gastric cancer death 
rate [2], gastric cancer is often diagnosed at advanced 
stages with distant metastases and carries a poor 
prognosis. In an effort to identify genes whose dysregula-
tion could be linked with the invasive capability of gastric 
cancer cells, investigators have reported multiple markers 
that could potentially contribute to the highly metastatic 
traits of gastric cancer [3]. Overexpression of CD24 was 
observed in gastric cancer tissue and was associated with 
increased lymph node metastasis and venous invasion of 
cancer cells, and CD24 was shown to directly affect gas-
tric cancer cell motility and invasive capability [4, 5].
CD24 is a mucin-like membrane glycoprotein and 
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expressed on normal endothelial cell and plateslets [6]. 
CD24 is also identified as a stem cell marker in intesti-
nal and colonic epithelial cells [7, 8]. Similarly, CD24 has 
also been shown to be expressed in stem cell subpopu-
lations from primary gastric, nasopharyngeal and colon 
tumors [9–11]. It is well known that negative expression 
of CD24 has been characterized as one of the biomark-
ers of breast cancer stem cells, resulting in functional 
promotion of breast tumor initiation and progression 
[12]. Interestingly, some reports also showed that CD24 
overexpression is associated with progression of breast 
cancer [13]. More recent evidence has revealed that 
CD24 is expressed predominantly by differentiated pari-
etal cells in the murine gastric corpus where it modulates 
gastric responses to H. felis and γ-radiation, so it appears 
not solely as a stem cell marker, but is also involved in 
regulating the homeostasis of gastric tissues [14]. Sev-
eral CD24 downstream effectors have been identified 
recently. For example, CD24 was shown to increase phos-
phorylation of FAK and paxillin, and enhance integrin-
dependent adhesion in breast cancer cells [15]. CD24 can 
stimulate STAT3 transcriptional activity via Src and sub-
sequently influence its oncogenicity [16, 17]. In colorectal 
cancer cells, CD24 was also observed to induce promoter 
activity and expression of the oncomir miR-21 via Src 
[18]. Although CD24 exerts its biological impacts based 
on multiple mechanisms, how CD24 contributes to gas-
tric cancer progression remains largely unknown.
Interestingly, an interaction between glycoproteins and 
growth factor-mediated signaling has been suggested 
to play a role in regulating tumor cell growth and sur-
vival, which revealed that metastatic tumors upregulate 
the expression of bulky glycoproteins, and suggested 
that these glycoproteins would influence transmem-
brane receptor spatial organization and function [19]. In 
fact, CD24 may affect the function of receptors such as 
CXCR4 [20] and HER2 [21], which are normally overex-
pressed in cancer cells. For example, CD24 was shown 
to support the expression of HER2 and contribute to 
decrease the sensitivity of HER2-positive breast cancer 
cells to lapatinib (HER2-targeted therapy) [21]. EGFR, a 
homodimer of ErbB1, is of particular importance in gas-
tric cancer, as its level of expression is increased during 
the progression of tumor progression and is correlated 
with reduced overall survival [22]. In the present study, 
we investigated the relevance of EGFR expression in 
CD24 positive gastric cancer. We here show that CD24 
positively regulates the expression of EGFR in gastric 
cancer cells, and that expression of CD24 supports the 
EGFR-PI3 K/Akt and EGFR-ERK signaling pathway. 
Interestingly, in SGC-7901 gastric cancer cells, CD24 
was shown to maintain the expression of EGFR through 
a RhoA-dependent manner. The results obtained in this 
study clearly established a novel relationship between 
CD24 and EGF/EGFR signaling in the context of migra-
tion regulation, which could be essential in promoting 
aggressiveness of gastric cancer.
Methods
Cells and plasmids
Human gastric cancer cell lines SGC-7901, BGC-823, 
AGS-1 and non-malignant gastric epithelial cells GES-1 
were obtained from the Cell Biology Institute of Chinese 
Academy of Sciences (Shanghai, China). Cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM, 
high glucose) (Hyclone, Thermo Scientific, Waltham, 
MA, USA) supplemented with 10  % (v/v) fetal bovine 
serum (FBS) (Hyclone) and antibiotics (100 U/mL strep-
tomycin and 100  μg/mL penicillin) (Invitrogen, Carls-
bad, CA, USA) in a humidified incubator at 37  °C with 
5 % CO2. Cells were grown on coverslips for fluorescence 
staining and on plastic dishes for protein extraction. Cells 
were made quiescent by serum starvation overnight fol-
lowed by drug treatment.
Full-length CD24 DNA was amplified using the following 
primer set, sense: 5′-CCCAAGCTTACCATGGGCAGA 
GCAATGGT-3′, antisence: 5′-CCGCTCGAGAGAGTA 
GAGATGCAGAAGAG-3′. In these primers, Hind III and 
XhoI restriction site sequences are italics. The polymer-
ase chain reaction (PCR) products were cloned into the 
pCMV-C-HA vector (Beyotime, Nantong, China).  The 
plasmid RhoA-V14 was kindly provided by Dr. Stéphane 
ORY (Institute of Cellular and Integrative Neurosciences, 
University of Strasbourg, France).
The cells were seeded in 6-well plates, cultured to 
60–70 % confluence, and then transiently transfected with 
those plasmids by using FuGENE HD Transfection Rea-
gent (Promega, Madison, WI, USA) in serum-free OPTI-
MEM according to the manufacturer’s instructions.
siRNA knockdown studies
The sequences of small interfering RNA (siRNA) for CD24 
were as follows: #1, 5′-GGAACUUCCAGGUGUUA-
CUTT-3′, #2, 5′-CCCACGCAGAUUUAUUCCATT-3′, 
and #3, 5′-GCUGGAGUUUCAUGUACAATT-3′. The 
sequence of siRNA for RhoA was: 5′-GAACUAUGUG 
GCAGAUAUCUUdTdT-3′ [23] and the sequence of con-
trol siRNA was 5′-UUCUCCGAACGUGUCACGUTT-3′ 
(GenePharmaCo., Shanghai, China). Cells were transfected 
with control siRNA, RhoA or CD24 siRNA with Lipo-
fectamine 2000 according to the manufacturer’s instruction.
Migration assay
SGC-7901 cells were seeded in a 96-well plate. Approxi-
mately 48  h later, when cells were 95–100  % confluent, 
wounding was performed by scraping through the cell 
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monolayer with a 10  µL pipette tip. Medium and non-
adherent cells were removed, and cells were washed 
twice with PBS, and fresh medium with or without EGF 
(R&D Systems, Minneapolis, MN, USA) was added. Cells 
were permitted to migrate into the area of clearing for 
18 h. Wound healing was photographed microscopically 
(Carl Zeiss Meditec, Jena, Germany).
For Transwell migration assay, SGC-7901 cells in expo-
nential growth were harvested, washed, and suspended in 
DMEM without FBS. Cells (2 × 105/200 μL) were seeded 
into polycarbonate membrane inserts (8  μm pore size) 
in 24-Transwell cell culture dishes. Cells were allowed to 
attach to the membrane for 30 min. The lower chamber 
was filled with 600 μL DMEM with EGF. Cells were per-
mitted to migrate for 6 h. After the incubation, stationary 
cells were removed from the upper surface of the mem-
branes. The cells that had migrated to the lower surface 
were fixed and stained with 0.1 % crystal violet. The num-
ber of stained cells was counted in photos taken by Nikon 
TS100 (Tokyo, Japan).
RT‑qPCR
Total RNAs were isolated with TRIzol reagent (Invitrogen). 
Equal amounts of RNA (1 μg) from each sample were used 
for cDNA synthesis and qPCR was performed on the ABI Ste-
pOne™ Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA) using GoTaq qPCR Master Mix assay (Pro-
mega) and analyzed using StepOne Software v2.1 (Applied 
Biosystems). 2−ΔΔCT method was used to calculate gene 
expression levels. For sample loading control, GAPDH was 
tested. The following primers were used to amplify CD24: 
5′-CTCCTACCCACGCAGATTTATTC-3′ (sense) and 
5′-AGAGTGAGACCACGAAGAGAC-3′ (antisense); EGFR: 
5′-CCCACTCATGCTCTACAACCC-3′ (sense) and 5′-TCG-
CACTTC TTACACTTGCGG-3′ (antisense); GAPDH: 5′-CAT 
CAGCAATGCCTCCTGCAC-3′ (sense) and 5′-TGAGTC 
CTTCCACGATACCAAAGTT-3′ (antisense).
Western blotting and coimmunoprecipitation analysis
Sample protein extraction and concentration deter-
mination of whole cells were performed as previously 
described [24]. Briefly, equal amounts of protein were run 
on SDS polyacrylamide gels and transferred to nitrocel-
lulose membrane. The resulting blots were blocked with 
5 % non-fat dry milk and probed with antibodie against 
the following proteins: GAPDH (KangChen Bio-tech, 
Shanghai, China), CD24 (BD Transduction Laboratories, 
Franklin Lakes, NJ, USA), EGFR and E-cadherin (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), RhoA, ERK, 
P-ERK, Akt, P-Akt (Cell Signaling Technology, Danvers, 
MA, USA). Protein bands were detected by incubat-
ing with HRP-conjugated antibodies (Santa Cruz Bio-
technology) and visualized with ECL reagent (Millipore, 
Billerica, MA, USA). Erlotinib (APExBio, Houston, USA), 
a selective EGFR inhibitor, was used to block EGFR-
mediated signaling.
Coimmunoprecipitation analysis was performed as 
previously described [25]. Briefly, proteins of indicated 
cells were pulled down with anti-EGFR antibody at 4 °C 
for 4  h, and then agarose beads conjugated to protein 
A+G were added to the supernatant of each sample and 
incubated with shaking at 4  °C for 1 h. After wash with 
rinsing buffer six times, agarose-associated protein com-
plexes were eluted using SDS loading buffer and analyzed 
by Western blotting assays.
Pulldown assays
For detection of active RhoA, equal amounts of total cel-
lular protein were incubated with GST-RBD (a gift from 
Dr. Keith Burridge, Department of Cell and Developmen-
tal Biology, University of North Carolina, Chapel Hill, 
NC) beads captured on MagneGST Glutathione Parti-
cles (Promega) at 4 °C with constant rotation for 30 min. 
The beads were washed three times with washing buffer 
(4.2 mmol/L Na2HPO4, 2 mmol/L KH2PO4, 140 mmol/L 
NaCl, and 10  mmol/L KCl, pH 7.2). At the end of this 
period, beads were captured by the magnet in a magnetic 
stand (Promega). After wash three times with ice-cold 
buffer, beads were resuspended in 2×SDS sample buffer 
and subjected to Western blotting assays by using anti-
RhoA antibody.
Immunofluorescence assays
Cells used for immunostaining were fixed in ice-cold 
methanol for 10  min, permeabilized in 0.1  % Triton 
X-100 and blocked in PBS containing 1 % BSA for 1 h at 
room temperature. The cells were incubated with anti-
body against EGFR or E-cadherin at 4  °C overnight fol-
lowed by incubation with rhodamine-conjugated or 
FITC-conjugated secondary antibody for 1  h at room 
temperature within a moist chamber. F-actin was stained 
with FITC-labeled phalloidin (5  μg/mL) (Sigma) for 
45 min at 37 °C. After wash with PBS, the samples were 
mounted with DAPI Fluoromount G (Southern Biotech, 
Birmingham, AL). Images were acquired using an Olym-
pus BX51 microscope coupled with an Olympus DP70 
digital camera.
Flow cytometry
A total of 1×106 cells were resuspended in 0.5  mL PBS 
containing 1  % BSA, and then incubated on ice for 
30  min. EGFR antibody (BD Biosciences) was added to 
cell suspension and incubated on ice for 30  min. Cells 
were washed and resuspended in 0.5 mL PBS containing 
fluro-labelled secondary antibody before analysis using a 
FACS Calibur Flow Cytometer (BD Biosciences).
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Immunohistochemistry
Tumor specimens used were obtained by the First Affili-
ated Hospital of Nanjing Medical University, the Affili-
ated Drum Tower Hospital of Nanjing University Medical 
School, the Affiliated Zhongda Hospital of Southeast 
University and the Second Affiliated Hospital of Nanjing 
Medical University (Nanjing, China). Forty-one primary 
human gastric tumor samples were used for immunohis-
tological staining in our CD24/EGFR expression correla-
tion study. The paraffin sections were deparaffinized and 
rehydrated. Peroxidase blocking was done with 3 % H2O2 
in methanol for 15  min at 37  °C. Antigen retrieval was 
performed by transferring the sections into EDTA buffer 
(pH 8.0). The sections were blocked in goat serum for 1 h 
and applied with EGFR or CD24 antibody at 4  °C over-
night. Then the sections were treated with the secondary 
antibody for 1 h at 37 °C, and washed in PBS. DAB sub-
strate solution was applied to reveal the color of antibody 
staining. After counterstaining with haematoxylin, the 
slides were mounted and the graphs were obtained using 
an Olympus BX51 microscope. Reagents for immunohis-
tochemistry were all obtained from ZSGB-BIO (Beijing, 
China). EGFR and CD24 immunostaining was analyzed 
by evaluation of the percentage of tumor-stained cells 
and staining intensity, allowing assessment of an immu-
noreactive score (IRS). The IRS was calculated as inten-
sity of the staining reaction multiplied by the percentage 
of positive cells as previously described [26, 27].
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical software program (Version 19.0; SPSS, Chicago, IL, 
USA). Data were analyzed by Student’s t test. P  <  0.05 
was considered to be significant (two tailed). In immu-
nohistochemistry, the difference in expression level of 
EGFR and CD24 was according to the IRS score, Pearson 
correlation test was used to examine association between 
EGFR and CD24 protein expressions.
Results
CD24 is overexpressed and regulates EGFR expression 
in gastric cancer cells
To assess the effect of CD24 on total EGFR level, we 
transfected human gastric cancer cells SGC-7901 with 
control siRNA or siRNA for CD24. The cells were lysed 
and total EGFR level was determined by Western blot-
ting. As shown in Fig.  1a, SGC-7901 cells transfected 
with siRNA against CD24 had a significantly lower level 
of EGFR than control cells. Two CD24 siRNAs (#1, #3) 
independently knocked down CD24 expression by more 
than 80  %, and siCD24 #3 was used in the subsequent 
experiments. We then evaluated EGFR and CD24 expres-
sion in malignant and non-malignant human gastric epi-
thelial cells by qPCR and Western blotting, and found 
that both EGFR and CD24 expressions at both the mRNA 
and protein level were increased in gastric cancer cells 
(SGC-7901 and BGC-823) compared to non-malignant 
Fig. 1 CD24 is associated with EGFR expression in gastric cancer cells. a SGC-7901 cells were transfected with negative control siRNA or siRNA spe-
cifically targeting CD24 (siCD24). Forty-eight h later, total protein extracts from cells were analyzed by western blotting analysis for CD24 and EGFR 
expression. Western blot bands corresponding to EGFR and CD24 were quantified and normalized against GAPDH. Asterisk P < 0.05 in the siCD24 
cells relative to siRNA control cells. b qPCR and c Western blotting assays of CD24 mRNA and protein expressions in GES-1, SGC-7901 and BGC-823 
cells. Data in (b) are presented as mean ± SD of 3 determinations asterisk P < 0.05 in the cultures of BGC-823, SGC-7901 relative to the cultures of 
GES-1. d BGC-823 cells transfected with control siRNA or siCD24 were lysed, EGFR and CD24 level was determined by Western blotting assays. e 
GES-1 cells were transfected with empty vector or CD24 plasmids, and the total cellular proteins were extracted and analyzed for expressions of 
EGFR by western blotting assays
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gastric epithelial cells (GES-1) (Fig.  1b, c). To confirm 
the role of CD24 in regulating EGFR expression, we also 
performed the same transfection in BGC-823, and found 
that siCD24 also inhibited the expression of EGFR in 
those cells (Fig. 1d). In contrast, an increase in the level of 
EGFR was observed in GES-1 cells (Fig. 1e) and BGC-823 
cells (Additional file  1: Figure S1) overexpressing CD24 
by Western blotting analyses. These results indicate that 
CD24 plays a positive role in regulating EGFR expression.
We further analyzed whether CD24 and EGFR were 
physically associated using co-immunoprecipitation 
assays, which showed that these two proteins were co-
precipitated in both SGC-7901 (Additional file  2: Figure 
S2A) and BGC-823 cells (Additional file  2: Figure S2B). 
We therefore next investigated whether there was a physi-
cal interaction between CD24 and EGFR. Notably, CD24 
and EGFR showed partial co-localization on the surface of 
BGC-823 cells (Additional file 2: Figure S2C). These data 
suggested that CD24 was physically associated with EGFR 
and thereby maintained its localization on the membrane.
CD24 knockdown affects EGFR function in gastric cancer 
cells
The MEK/ERK and the PI3 K/Akt pathways are two of 
the better-understood EGFR signal transduction path-
ways involved in cell migration. Since the knockdown of 
CD24 by siRNA inhibited EGFR expression, we further 
analyzed the effect of CD24 on EGFR related signaling 
pathway in gastric cancer cells. Normally, phosphoryla-
tion of ERK and PI3 K/Akt keeps high level in SGC-7901 
cells. As expected, EGFR downstream effectors ERK and 
Akt were phosphorylated less in siCD24 transfected cells 
compared with controls (Fig.  2a). It is well known that 
erlotinib is a potent selective blocker of EGFR-mediated 
signaling. Additional file 3: Figure S3 shows that the pro-
tein levels of P-Akt and P-ERK markedly increased in 
CD24-overexpressing GES-1 cells, which was attenuated 
by erlotinib. Moreover, an increase of P-Akt and P-ERK 
by EGF stimulation was markedly inhibited by erlo-
tinib. SiEGFR has been reported to reverse EGF-induced 
E-cadherin low-expression as well as down-regulating 
Fig. 2 Effects of siCD24 on EGFR downstream proteins and cell migration. a SGC-7901 cells transfected with control siRNA or siCD24, and protein 
levels of EGFR, P-ERK, ERK, P-Akt, Akt and E-cadherin were examined. b Representative immunofluorescence images of SGC-7901 cells transfected 
with control siRNA or siCD24 stained for E-cadherin. Scale bar, 10 μm. c A representative of wound healing assays in SGC-7901 cells transfected with 
control siRNA or siCD24 is presented, and the quantification of cell migration rate was performed. Data are presented as mean ± SD of 8 determina-
tions asterisk P < 0.05 in the siCD24 cells relative to siRNA control cells. d Control and siCD24 SGC-7901 Cell migration rate was also evaluated by 
Transwell migration assay. Data are presented as mean ± SD of 3 determinations asterisk P < 0.05 in the siCD24 cells relative to control cells
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subsequent cell invasion in human oviductal epithe-
lial cells [28], so we next analyzed whether knockdown 
of CD24 affected the total level and distribution of 
E-cadherin in SGC-7901 cells. Interestingly, our results 
revealed that the expression of E-cadherin in control cells 
was weak and large amounts of E-cadherin were local-
ized in the cytoplasm. However, after transfection with 
siCD24, E-cadherin abundance was obviously increased, 
and substantial E-cadherin localization was observed, 
especially in the cellular membrane (Fig. 2a, b). We also 
found that siCD24-expressing cells exhibited decreased 
migratory potential than the control cells (Fig.  2c, d). 
Taken together, these observations suggest that CD24 
knockdown impairs EGFR function in gastric cancer 
cells.
CD24 affects EGFR internalization and degradation 
in gastric cancer cells
To directly test the functional role of CD24 in EGFR 
expression, we firstly performed quantitative PCR 
(qPCR) to evaluate the effect of siCD24 on EGFR tran-
scriptional expression. Whereas cells transfected with 
siCD24 underwent marked reduction in CD24 mRNA 
expression, the abundance of EGFR mRNA was not 
affected in serum or serum-free conditions in SGC-7901 
cells (Fig. 3a). We thus reasoned that CD24 may modu-
late EGFR expression by suppressing its distribution in 
the cytoplasm and the subsequent degradation process. 
To investigate this possibility, flow cytometry was per-
formed and the results revealed a significant decrease in 
the staining intensity of EGFR on the membrane in cells 
transfected with CD24 siRNA in both SGC-7901 (Fig. 3b) 
and BGC-823 cells (Fig.  3c). In contrast, immunofluo-
rescence staining showed an increase in the staining of 
EGFR in the cytoplasm and a decrease in EGFR at the 
membrane in siCD24 transfected cells. FITC-Phalloidin 
was used to outline cell membrane (Fig. 3d). Collectively, 
these data suggest that CD24 modulates EGFR subcellu-
lar location in gastric cancer cells.
Knockdown of CD24 downregulates EGFR expression 
through RhoA in SGC‑7901 cells
Although CD24 was proved to be involved in maintaining 
EGFR expression, the precise mechanism underlying this 
regulation was poorly known. Considering the impor-
tance of Src in regulating receptor internalization [29], 
and CD24 has been reported to interact with Src [15], in 
initial experiments, we treated SGC-7901 and BGC-823 
cells with PP2  (Alexis Biochemicals), an Src inhibitor, 
and examined whether PP2 inhibited EGFR expression 
and CD24 association of EGFR in our experimental sys-
tem. Although we observed that PP2 did not substan-
tially change the expression levels of CD24 in BGC-823 
cells and SGC-7901 cells, significant decrease in EGFR 
expression was observed in BGC-823 cells, but not SGC-
7901 cells (Fig.  4a). We also noticed that, in BGC-823 
cell line, the association between CD24 and EGFR was 
significantly decreased in PP2-treated cells than that in 
untreated cells. However, PP2 treatment had no effect on 
the association between CD24 and EGFR in SGC-7901 
cells (data not shown), suggesting that Src kinase activity 
may be required for CD24 to keep EGFR expression in 
BGC-823 cells, but not in SGC-7901 cells.
The activity of RhoA is known to play an important role 
in the internalization of EGFR [30]. We thus reasoned 
that RhoA may be involved in the regulation of EGFR 
stability downstream of CD24 in SGC-7901 cells. To 
investigate this possibility, we performed pulldown assay 
to detect RhoA activity in SGC-7901 cells transfected 
with siCD24. Interestingly, RhoA activity was decreased 
after knockdown of CD24, as shown by Western bloting 
assays (Fig. 4b), while RhoA knockdown by siRNA led to 
the noticeable decrease of EGFR expression in SGC-7901 
cells (Fig. 4c). The protein level of EGFR was significantly 
higher in RhoA-V14 transfected cells, compared to the 
controls (Fig. 4d). Taken together, these findings demon-
strate that RhoA function is necessary for CD24-medi-
ated EGFR stability in gastric cancer SGC-7901 cells.
Effects of EGF stimulation on EGFR expression 
and distribution in gastric cancer cells expressing low 
levels of CD24
To further analyze the effect of CD24 on EGFR stability 
and following signaling pathway, SGC-7901 cells were 
transfected with siCD24 and stimulated with EGF for 
different spans of time. As shown in Fig.  5a–c, knock-
down of CD24 expression accelerates EGFR degradation 
in SGC-7901, AGS-1 and BGC-823 cells. Interestingly, 
ERK and Akt (EGFR main downstream effectors) were 
also phosphorylated less in siCD24 transfected cells 
compared with controls (Additional file  4: Figure S4). 
This observation suggests a decrease in EGFR signaling 
activation induced by CD24 low-expression. Moreover, 
depletion of CD24 induced a marked increase in EGFR 
concentration in the cytoplasm in spite of EGF stimula-
tion in SGC-7901 (Fig. 5d) and AGS-1 cells (Fig. 5e). To 
discriminate between protein synthesis and degrada-
tion, we blocked translation by treating the cells with 
cycloheximide (CHX). As shown in Fig.  5f, silencing 
CD24 expression significantly accelerated EGFR degrada-
tion stimulated by EGF.
Expression of EGFR in gastric cancer correlates with CD24 
expression
To investigate whether our experimental findings could 
be relevant to the pathogenesis of gastric cancer in 
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Fig. 3 Downregulation of CD24 alters the localization and degradation of EGFR. a The mRNA levels of CD24 and EGFR were detected by qPCR in 
SGC-7901 cells transfected with control siRNA or siCD24. b and c The level of EGFR on cellular membrane of SGC-7901 cells (b) and BGC-823 cells 
(c) was measured using flow cytometry. d Representative immunofluorescence images of SGC-7901 cells transfected with control siRNA or siCD24 
staining for EGFR and phalliodin. Scale bar 10 μM. Asterisk P < 0.05 in the siCD24 cells relative to siRNA control cells
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humans, we examined CD24 and EGFR expression 
patterns in high and low degree differentiated gas-
tric cancers. Representative results of CD24 and EGFR 
immunostaining of gastric cancer are shown in Fig.  6a, 
c. Among 41 gastric cancer cases, we found that both 
CD24 and EGFR expression level was markedly increased 
in low-differentiated tumor tissues when compared 
with their matched highly-differentiated tumor tissues 
(Fig. 6b, d). Furthermore, immunostaining of CD24 and 
EGFR in the samples revealed a positive correlation in 
expression (r = 0.4411, P < 0.01) (Fig. 6e, f ). Overall, the 
clinical data support our in vitro results that CD24 may 
play a role as an EGFR supporter to promote gastric can-
cer progression.
Discussion
Aberrant activation CD24 signaling contributes to 
malignant progression of gastric cancer has been dem-
onstrated recently [4, 17]. Here, we investigated the 
relationship between CD24 and EGFR in gastric cancer 
cells. We demonstrated here that knockdown of CD24 
accelerates internalization and decreases membranous 
stability of EGFR, leading to an impaired EGFR signal-
ing cascade as well as cell migration. Moreover, we found 
that CD24-mediated activation of RhoA is required 
for maintaining EGFR expression. Moreover, analysis 
of gastric cancer specimens also showed a positive cor-
relation between CD24 and EGFR expression. Together, 
our results indicate that CD24 plays an important role in 
regulating EGFR and EGFR-initiated signaling in gastric 
cancer.
EGFR is a well-studied transmembrane receptor that 
activates intracellular signaling cascades and controls 
most vital cellular processes such as survival and cell 
motility [31]. Accordingly, upregulation of EGFR expres-
sion is central to gastric cancer cell metastatic behavior 
[32]. In the present study, the fact that depletion of CD24 
leading to low expression of EGFR in gastric cancer cells 
attracted our attention. Because the gastric cancer tissue 
samples we studied here were from China, we used the 
two gastric cancer cell lines derived from Chinese gas-
tric carcinoma patients to study the regulation of EGFR 
by CD24. Consistent with the in vivo data, which showed 
a positive correlation between CD24 and EGFR levels in 
gastric cancer specimens, our in  vitro results revealed 
that CD24 expression was higher in SGC-7901 and 
BGC-823 cells, which also showed remarkably increased 
expression of EGFR than normal gastric epithelial cells. 
Fig. 4 RhoA, but not Src, medicates EGFR expression by CD24 in SGC-7901 cells. a SGC-7901 and BGC-823 cells were treated with 20 μM PP2.  
30 min later, and total protein extracts from cells were analyzed by Western blotting assays for CD24 and EGFR expression. b SGC-7901 cells were 
transfected with control siRNA or siCD24, and the activity of RhoA was measured. RhoA-GTP bands were quantified and normalized against RhoA 
level (graph on the right). Asterisk P < 0.05 in the siCD24 cells relative to siRNA control cells. c SGC-7901 cells were transfected with control siRNA or 
siRhoA, and the expressions of RhoA and EGFR were measured. EGFR bands were quantified and normalized against GAPDH (graph on the right). 
Asterisk P < 0.05 in the siCD24 cells relative to siRNA control cells. d SGC-7901 cells were transfected with GFP-tagged empty vector or RhoA-V14 
plasmids, and the total cellular proteins were extracted and analyzed for expression of EGFR by Western blotting assays. Asterisk P < 0.05 in the CD24 
overexpressing cells relative to control cells
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Moreover, we also noticed that overexpression of CD24 
elevated EGFR expression in GES-1 gastric epithelial 
cells. Those results revealed a further mechanism worth 
exploring for the high amount of EGFR in gastric can-
cer, especially as CD24 expression itself correlates with a 
poor prognosis [33, 34].
Although CD24 was detected on the cytoplasm in gas-
tric cancer cells as other report suggested [35], we were 
surprised to observe that CD24 was localized to the 
cell membrane, where it was partially co-localized and 
interacted with EGFR. This suggests that CD24 might 
have wider roles in cellular processes, such as modulat-
ing EGFR membranous stability. EGFR signaling path-
way activation is primarily mediated by activated EGFR 
located in the plasma membrane [36]; then, several dif-
ferent downstream signaling pathways are activated. 
Interestingly, EGFR was found to be co-localized with 
another membrane glycoprotein CD44 in lipid rafts, 
and such co-localization could trigger downstream 
ERK and Ca2+/CaMKII activation, which were essential 
Fig. 5 Effects of EGF on EGFR expression and distribution in gastric cancer cells with knockdown of CD24. a SGC-7901 b BGC-823 and c AGS-1 cells 
transfected with control siRNA or siCD24 were in serum-free media overnight and incubated with EGF 20 ng/mL for indicated times, and then pro-
teins extracted from the lysates were subjected to Western blotting assays to detect the expression of EGFR. GAPDH is used for control. d SGC-7901 
and e AGS-1 cells transfected with control siRNA or siCD24 were in serum-free media overnight and incubated with EGF 20 ng/mL for 15 min, and 
representative microscopy images of SGC-7901 and AGS-1 cells stained for EGFR are shown. Cell nuclei were labeled with DAPI. Scale bar 10 μm. 
f SGC-7901 cells transfected with control siRNA or siCD24 were in serum-free media overnight. In addition to its protein synthesis blocked with 
cycloheximide (CHX, 10 μg/mL), the cells were then stimulated with EGF (20 ng/mL) for the indicated times. Then, the cells were lysed and EGFR 
level was determined by Western blotting assays. EGFR bands were quantified and normalized against GAPDH (graph on the right). Asterisk P < 0.05 
in the siCD24 cells relative to siRNA control cells
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Fig. 6 CD24 expression is relative with the low degree differentiation of malignant gastric cancer and has a positive correlation with EGFR. The IRS 
is calculated as intensity of the staining reaction multiplied by the percentage of positive cells. Based on the IRS values, CD24 and EGFR were scored 
as weak, medium and strong in the following parts. a High and low degree differentiated malignant gastric cancer tissue sections were stained 
against CD24. Brown, CD24; Blue, haematoxylin. b IRS scores of CD24 according to tumor histological grade. c High and low degree differentiated 
malignant gastric cancer tissue sections were stained against EGFR. Brown, EGFR; Blue, haematoxylin. d IRS scores of EGFR according to tumor 
histological grade. e Using serial sections of the same sample, representative high and low degree differentiated malignant gastric cancer tissue 
stained for CD24 and EGFR are shown. f The scatterplot of correlated protein levels between CD24 and EGFR in high and low degree differentiated 
malignant gastric cancer tissue (n = 41). Scale bar 100 μm
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for TGF-β-stimulated fibroblast to myofibroblast dif-
ferentiation [37]. The PI3 K/Akt and ERK pathways are 
important among them and have been implicated in can-
cer cell growth and migration [38]. Interestingly, recent 
studies showed that the downregulation of membranous 
E-cadherin is mediated by Akt or ERK activation [39, 
40]. In this report, SGC-7901 gastric cancer cells deplet-
ing CD24 showed significant reductions in phospho-
rylation of ERK and Akt proteins as well as increases in 
E-cadherin expression levels. Moreover, E-cadherin was 
re-localized at cell-to-cell contacts and cell motility was 
reduced in those cells. Overall, the fact that CD24 inter-
acted with EGFR and was crucial for activation of EGFR 
downstream effectors and cell migration, allowing us to 
conclude that regulation of EGFR stabilized expression 
can thus be a novel mechanism for CD24-induced gastric 
cancer progression.
Endocytosis of EGFR occurs in either a ligand-
dependent or a ligand-independent way. Under normal 
conditions (serum-containing medium), EGFR can be 
constitutively internalized in the absence of EGF. After 
internalization, receptors are either recycled back to the 
cell surface, or sorted into intraluminal vesicles and sub-
sequently delivered to lysosome for degradation to ter-
minate EGFR activation [41, 42]. In breast cancer cells, 
CD24 is suggested to increase HER2 expression by tran-
scriptional machineries via NF-κB signaling [21]. Here, 
we identified that CD24 maintains EGFR expression via 
reduction of EGFR internalization and degradation, but 
not by inhibition of its production. Another phenomenon 
we noticed here was that, in serum-starved conditions, 
CD24-knockdown cells had lower EGFR expression com-
pared to control cells, and such difference was apparent 
before and after the gastric cancer cells were stimulated 
with EGF. In accordance with this, the Akt and ERK path-
ways are less activated by EGF in those cells. This result 
suggests that CD24 may regulate the basal level of EGFR. 
Notably, plasmatic EGFR staining was more visible and 
concentrated in CD24 knockdown cells in spite of EGF 
treatment. This lends support to the idea that CD24 may 
prevent EGFR internalization and degradation in the 
cytoplasm by an EGF-dependent or EGF-independent 
way.
How CD24 maintains EGFR expression on the cell sur-
face remains unknown. On the membrane, EGFR and 
CD24 share interactions with several proteins including 
the non-receptor tyrosine kinase Src [15, 43–45]. CD24 
is well known as the regulator of Src activity and Src-
induced STAT3 and FAK activity [15, 16]. Recent work 
has also highlighted a co-localization between Src with 
EGFR, particularly within lipid rafts of cancer cells [46], 
Moreover, it was reported that Src could phosphorylate 
EGFR [47, 48], and mediate EGFR signaling in various 
cancer cell lines [46, 49]. However, in our study for SGC-
7901 cells, loss of Src activation is unlikely to alter the 
kinetics of EGFR expression greatly. Therefore, additional 
proteins or molecules that play roles in the association 
between CD24 and EGFR remain to be identified. Given 
that the Rho GTPase subpopulation is thought to regu-
late EGFR endocytosis and trafficking [50], it appeared 
that Rho GTPases may be involved in the regulating 
process.
Three most common members of the Rho family are 
Rac1, Cdc42 and RhoA. All of them were recorded to par-
ticipate in cellular endocytotic and recycling pathways. 
For example, activated Rac1 binds to F-actin cross-link-
ing protein IQGAP1, and then inhibits the endocytosis 
of E-cadherin [51]. Cdc42 participates in the transport of 
glycoprotein of vesicular stomatitis virus (VSV-G) from 
the ER into the Golgi apparatus [52]. RhoA reportedly 
mainly participates in endocytic transport regulation [53, 
54]. In some cell types, RhoA/ROCK is a downstream 
target of EGFR activation, which then turns off the acti-
vated EGFR pathway via a negative feedback system [55]. 
However, when we analyzed the role of RhoA protein 
on EGFR stability in gastric cancer cells, we observed 
that the inhibition of RhoA impaired EGFR expression 
and active RhoA markedly increased EGFR expression. 
Importantly, CD24-knockdown cells had lower RhoA 
activation compared to control cells. In accordance with 
this, a mathematical model has shown that over-express-
ing RhoA as well as its downstream effector ROCK could 
prolong ERK activation partly by reducing EGFR endocy-
tosis [56]. Similarly, RhoA is required for delayed EGFR 
degradation in Vav2-overexpressing HeLa cells stimu-
lated with EGF [57]. Mierke CT et al. have also reported 
that lung cancer cell invasiveness was reduced after pre-
treatment with ROCK inhibitor Y27632 in CD24high cells, 
but not in CD24neg cells [58]. Indeed, RhoA and ROCK 
have been shown to be negatively associated with EGFR 
endocytosis. Early studies indicated that the active form 
of ROCK can inhibit the recruitment of endophilin A1 to 
the EGFR-c-Cbl-CIN85 complex, leading to the reduc-
tion of EGFR endocytosis in PC-12D cells [30]. Hence, 
the observation here explained, at least in part, the 
requirement of RhoA activation for CD24-mediated sta-
ble EGFR expression.
Together, these data point to the ability of CD24 to 
regulate EGFR signaling by preventing EGFR internaliza-
tion and degradation through RhoA. Given that CD24 is 
a major GPI-anchored and lipid rafts-associated protein, 
it is possible that it may recruit and restrict lipid raft-
localization of EGFR on the membrane. Hence, in CD24-
positive cancer cells, EGFR keeps its association with 
lipid rafts on the membrane that is necessary for its sign-
aling transduction and reducing its internalization and 
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degradation. These findings are of potential pathophysi-
ological importance for understanding the integration 
of CD24-related signaling and shed light on anti-CD24 
therapy for gastric cancer.
Additional files
Additional file 1: Figure S1. Effect of CD24 overexpression on EGFR 
level in BGC-823 cells. BGC-823 cells were transfected with empty vector 
or CD24 plasmids, and the total cellular proteins were extracted and ana-
lyzed for expression of EGFR by Western blotting assays.
Additional file 2: Figure S2. CD24 forms complexes with EGFR. (A&B) 
Co-immunoprecipitation of CD24 by EGFR was determined. SGC-7901 
cells (A) or BGC-823 cells (B) were immunoprecipitated with anti-EGFR 
antibody, followed by Western blotting assays for CD24. The second 
top panel shows immunoprecipitated CD24. The third top panel shows 
GAPDH bands in samples of input and immunoprecipitation. After pull-
down, the supernatant was also subjected to Western blotting assays to 
detect the expression of GAPDH. (C) Representative micrographs of BGC-
823 cells stained for CD24 (red) and EGFR expression (green) by immu-
nofluorescence staining. The arrow shows that co-location of CD24 and 
EGFR. Scale bar, 10 μm. n = 3 for all experiments.
Additional file 3: Figure S3. Effect of EGFR inhibitor erlotinib on P-Akt 
and P-ERK levels in CD24 overexpressed GES-1 cells. GES-1 cells trans-
fected with empty vector or CD24 plasmids were incubated with 1 μM 
erlotinib, or the cells in serum-free media overnight, then the cells were 
treated with EGF (20 ng/mL) for 20 min after erlotinib incubation. Proteins 
extracted from the lysates were subjected to Western blotting assays to 
detect the expression of P-Akt and P-ERK.
Additional file 4: Figure S4. Effect of CD24 silencing on EGF-induced 
phosphorylation of ERK and Akt. SGC-7901 cells transfected with con-
trol siRNA or siCD24 were cultured in serum-free media overnight and 
incubated with EGF 20 ng/mL for indicated times, and then the proteins 
extracted from the lysates were subjected to Western blotting assays to 
detect the expression of proteins as indicated.
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